We have completed the nonclinical toxicology and immunogenicity evaluations of IMU-201 (administered IM as PD1-Vaxx) in male and female cynomolgus monkeys that have a high degree (>90%) of PD-1 sequence homology to humans, including 100% homology for the 19 PD-1 amino acids in MVF-PD-1 (92-110), prior to initiating clinical trials on IMU-201 in cancer patients. The gene discussed is PDCD1; the disease is cancer.